Fulgent Genetics Partners with Foundation Medicine to Advance Cancer Risk Assessment Technology

Foundation Medicine and Fulgent Genetics Join Forces to Enhance Cancer Risk Assessment

Foundation Medicine, Inc. announces the impending launch of two innovative germline tests aimed at revolutionizing cancer care in the United States. Collaborating with Fulgent Genetics, Inc., these tests—FoundationOne® Germline and FoundationOne® Germline More—are set to debut on February 28, 2025. They are specifically designed to identify genetic variants associated with hereditary cancers, enabling healthcare providers to better assess risks for patients and their families. This strategic partnership reflects a commitment to improving patient outcomes through advanced genomic testing.

FoundationOne Germline focuses on a targeted analysis of 50 genes linked to hereditary cancers, making it particularly useful for individuals with pertinent personal or family histories. In contrast, FoundationOne Germline More expands its scope to analyze 154 genes, catering to patients with more complex clinical presentations. Annie Murphy, Chief Commercial Officer at Foundation Medicine, underscores the importance of these tests, stating that they will furnish critical insights into the origins of cancer, thereby enhancing the risk assessment process for both healthcare providers and patients. The integration of these germline tests with Foundation Medicine’s existing genomic profiling tests creates a more robust molecular profile, ultimately driving personalized cancer care.

Fulgent Genetics plays a pivotal role in this development by providing proprietary technology that enhances the examination of genetic variations. Brandon Perthuis, Chief Commercial Officer at Fulgent, emphasizes the significance of combining germline and somatic testing. This integration strengthens patient care by promoting a comprehensive understanding of genetic factors influencing cancer. The collaboration between Foundation Medicine and Fulgent Genetics not only represents a significant advancement in molecular profiling but also reflects the companies' shared vision of enhancing clinical care and research in the field of oncology.

In addition to these tests, the partnership signifies a broader trend in the healthcare industry toward precision medicine, where tailored treatment options based on individual genetic profiles are becoming increasingly accessible. As molecular profiling continues to evolve, the collaboration between these two industry leaders positions them at the forefront of innovation in cancer care.

The launch of FoundationOne Germline and FoundationOne Germline More highlights the potential for improved risk assessments in hereditary cancers, offering hope to patients and families navigating these challenges. With a commitment to advancing cancer care, Foundation Medicine and Fulgent Genetics are set to make significant strides in the understanding and management of genetic risks associated with cancer.